Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”

被引：0

作者：

Florence Namour

机构：

[1] Galapagos SASU,

来源：

Clinical Pharmacokinetics | 2015年 / 54卷

关键词：

Active Metabolite; Maximum Plasma Concentration; Population Pharmacokinetic Model; Population Pharmacokinetic Analysis; JAK1 Inhibitor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1297 / 1298

页数：1

共 45 条

[21] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE AS MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
Kavanaugh, A.
Ponce, L.
Cseuz, R.
Reshetko, O.
Stanislavchuk, M.
Greenwald, M.
Van der Aa, A.
Vanhoutte, F.
Tasset, C.
Harrison, P.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 247 - 247
[22] THE EFFECT OF FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR ON PATIENT-REPORTED OUTCOMES: RESULTS FROM TWO 24-WEEK PHASE 2B DOSE RANGING STUDIES
Genovese, M.
Westhovens, R.
Kavanaugh, A.
Meuleners, L.
Van der Aa, A.
Harrison, P.
Tasset, C.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 244 - 244
[23] Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions.
Florence, Namour
Julie, Desrivot
Van der Aa, Annegret
Tasset, Chantal
van 't Klooster, Gerben
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S651 - S651
[24] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis
Vermeire, Severine
Schreiber, Stefan
Petryka, Robert
Kuehbacher, Tanja
Hebuterne, Xavier
Roblin, Xavier
Klopocka, Maria
Goldis, Adrian
Wisniewska-Jarosinska, Maria A.
Baranovsky, Andrei
Sike, Robert
Tasset, Chantal T.
Van der Aa, Annegret
Harrison, Pille
GASTROENTEROLOGY, 2016, 150 (04) : S1267 - S1267
[25] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
Westhovens, R.
Alten, R.
Pavlova, D.
Sosa, F. E. Enriquez
Mazur, M.
Greenwald, M.
Van der Aa, A.
Vanhoutte, F.
Tasset, C.
Harrison, P.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 142 - 142
[26] EFFICACY AND SAFETY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR, AFTER SHORT-TERM TREATMENT OF RHEUMATOID ARTHRITIS; RESULTS OF A PHASE IIA TRIAL
Vanhoutte, F. P.
Mazur, M.
Namour, F.
van der Aa, A.
Wigerinck, P.
van 't Klooster, G. A. E.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 145 - 145
[27] IDENTIFICATION OF A GENE SIGNATURE AND RESPONSE BIOMARKERS IN CIRCULATING LEUKOCYTES OF RA PATIENTS AFTER TREATMENT WITH THE JAK1-SELECTIVE INHIBITOR FILGOTINIB (GLPG0634)
Ongenaert, M.
Dupont, S.
Vayssiere, B.
Meuleners, L.
Brys, R.
Galien, R.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1068 - 1068
[28] Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
Kavanaugh, A.
Kremer, J.
Ponce, L.
Cseuz, R.
Reshetko, O. V.
Stanislavchuk, M.
Greenwald, M.
Van der Aa, A.
Vanhoutte, F.
Tasset, C.
Harrison, P.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 1009 - 1019
[29] Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor
Vermeire, S.
De Hertogh, G.
Chen, G.
French, D.
Huntzicker, E.
Van der Aa, A.
Van Kaem, T.
Harrison, P.
Tasset, C.
Galien, R.
Pan, Y.
Feagan, B.
Sandborn, W.
JOURNAL OF CROHNS & COLITIS, 2017, 11 : S20 - S21
[30] SAFETY AND EFFICACY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A 4-WEEK PHASE II A DOSE RANGING, MULTI-CENTER TRIAL
Vanhoutte, F. P.
Van der Aa, A.
Meuleners, L.
van 't Klooster, G.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 242 - 242

← 1 2 3 4 5 →